EOLS vs. VREX, MNMD, PRAX, SILK, PRTC, DNTH, TMCI, SVRA, ENGN, and KIDS
Should you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Varex Imaging (VREX), Mind Medicine (MindMed) (MNMD), Praxis Precision Medicines (PRAX), Silk Road Medical (SILK), PureTech Health (PRTC), Dianthus Therapeutics (DNTH), Treace Medical Concepts (TMCI), Savara (SVRA), enGene (ENGN), and OrthoPediatrics (KIDS). These companies are all part of the "medical" sector.
Varex Imaging (NASDAQ:VREX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings.
90.7% of Evolus shares are held by institutional investors. 5.2% of Varex Imaging shares are held by company insiders. Comparatively, 5.4% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Varex Imaging currently has a consensus price target of $27.00, suggesting a potential upside of 60.14%. Evolus has a consensus price target of $20.60, suggesting a potential upside of 81.02%. Given Varex Imaging's higher probable upside, analysts plainly believe Evolus is more favorable than Varex Imaging.
Varex Imaging has a net margin of 5.08% compared to Varex Imaging's net margin of -30.52%. Evolus' return on equity of 9.21% beat Varex Imaging's return on equity.
In the previous week, Varex Imaging had 2 more articles in the media than Evolus. MarketBeat recorded 3 mentions for Varex Imaging and 1 mentions for Evolus. Evolus' average media sentiment score of 0.60 beat Varex Imaging's score of 0.50 indicating that Varex Imaging is being referred to more favorably in the media.
Varex Imaging has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Varex Imaging, indicating that it is currently the more affordable of the two stocks.
Evolus received 108 more outperform votes than Varex Imaging when rated by MarketBeat users. Likewise, 71.82% of users gave Evolus an outperform vote while only 63.64% of users gave Varex Imaging an outperform vote.
Varex Imaging has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Summary
Varex Imaging beats Evolus on 9 of the 17 factors compared between the two stocks.
Get Evolus News Delivered to You Automatically
Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
